glp 1 gip receptor agonist The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology Effects, working principles and target
Description
10.2165/00002018-200629100-00005 4 AlsaadounA
Eligibility is based on BMI of 35 or more alone, or 27 or more plus other clinical criteria
individual results vary
Previewing biopharma commercial, market access and development themes
Provenance and peer review: Not commissioned
